NCT06625593 2026-04-22
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
15 trialsNCT04855656 2026-04-20
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06597721 2026-04-17
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
Phase 1 Recruiting
NCT07380334 2026-04-16
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07226349 2026-04-15
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06143774 2026-04-13
Study of TRX-920 for Patients With Advanced Solid Tumors
TaiRx, Inc.
Phase 1 Recruiting
NCT06352359 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Recruiting
NCT06635785 2026-04-09
BiPAVE-001
OncoC4, Inc.
Phase 1/2 Recruiting
NCT06911827 2026-04-07
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06672185 2026-04-03
ARC101 in Advanced Solid Tumors
Third Arc Bio
Phase 1 Recruiting
NCT06833008 2026-03-31
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07300943 2026-03-25
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting